Jaktinib Hydrochloride Tablets

DRUG13 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Acute Graft-Versus-Host DiseaseAlopecia AreataAnkylosing SpondylitisCOVID-19Healthy SubjectsHealthy VolunteersHepatic InsufficiencyIdiopathic Pulmonary Fibrosis

Phase 1

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

CompletedNCT04993404

Suzhou Zelgen Biopharmaceuticals Co.,LtdHealthy Subjects, Hepatic Insufficiency

Start: 2021-08-27End: 2022-09-19Updated: 2024-01-11

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

CompletedNCT06132243

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2023-11-29End: 2023-12-20Updated: 2024-01-11

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

CompletedNCT06246695

Suzhou Zelgen Biopharmaceuticals Co.,LtdHealthy Volunteers

Start: 2021-10-27End: 2022-01-12Updated: 2024-02-07

Phase 2

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

CompletedNCT03886415

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2019-01-08End: 2021-02-02Updated: 2022-11-29

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

CompletedNCT04034134

Suzhou Zelgen Biopharmaceuticals Co.,LtdAlopecia Areata

Start: 2019-11-18End: 2021-11-26Updated: 2022-11-29

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

CompletedNCT04217993

Suzhou Zelgen Biopharmaceuticals Co.,LtdPost-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Primary Myelofibrosis (PMF)

Start: 2020-01-07End: 2022-08-03Updated: 2023-04-20

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

CompletedNCT04312594

Suzhou Zelgen Biopharmaceuticals Co.,LtdIdiopathic Pulmonary Fibrosis

Start: 2020-09-08End: 2022-06-09Updated: 2024-12-12

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

CompletedNCT04507659

Suzhou Zelgen Biopharmaceuticals Co.,LtdAnkylosing Spondylitis

Start: 2020-12-01End: 2022-08-02Updated: 2023-03-29

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

CompletedNCT04851535

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2021-07-28End: 2022-11-01Updated: 2023-11-03

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Not yet recruitingNCT04971551

Suzhou Zelgen Biopharmaceuticals Co.,LtdAcute Graft-Versus-Host Disease

Start: 2024-12-31End: 2025-07-31Target: 60Updated: 2024-03-06

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Suzhou Zelgen Biopharmaceuticals Co.,LtdNovel COVID-19-Infected Pneumonia

Start: 2024-04-30End: 2025-03-31Target: 120Updated: 2023-10-24

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Suzhou Zelgen Biopharmaceuticals Co.,LtdNovel COVID-19-Infected Pneumonia

Start: 2024-04-30End: 2025-03-31Target: 60Updated: 2023-10-24

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

WithdrawnNCT05702788

Suzhou Zelgen Biopharmaceuticals Co.,LtdCOVID-19, Pneumonia

Start: 2022-09-30End: 2024-04-23Updated: 2024-04-26

Related Papers

Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial

RMD Open2025-01-011 citations

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Mielofibrose

Epidemiologia e Serviços de Saúde2025-01-01

Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial.

2024-07-201 citations

Association between ferritin, hemoglobin, and anemia response in jaktinib-treated patients with myelofibrosis: A post-hoc analysis of the ZGJAK006 study.

Journal of Clinical Oncology2024-06-01

S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS

HemaSphere2023-08-013 citations

A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).

Journal of Clinical Oncology2023-06-016 citations

Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.

Journal of Clinical Oncology2023-06-012 citations

Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.

Journal of Clinical Oncology2023-06-01